Literature DB >> 3930972

Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes.

U R Rapp, J L Cleveland, K Brightman, A Scott, J N Ihle.   

Abstract

Several oncogenes are thought to cause transformation by affecting the signal transmission pathway of growth factors. One example is the induction of c-myc, the cellular homologue of the avian transforming oncogene v-myc, by platelet-derived growth factor (PDGF) among a set of genes associated with competence induction in fibroblasts. Another of the competence genes, r-fos, has been shown to be related to v-fos, the transforming gene of the FBJ sarcoma virus. In addition, PDGF induces c-fos, the cellular homologue of v-fos. The importance of c-myc induction is suggested by the observation that c-myc, under the control of a glucocorticoid regulator, can partially relieve the requirement of fibroblasts for PDGF. We have examined the effects of oncogenes on haematopoietic/lymphoid cell differentiation, immortalization and factor dependence for growth. Here we report the effects of recombinant murine retroviruses capable of expressing the avian v-myc. With interleukin-3 (IL-3)- or interleukin-2 (IL-2)-dependent cells, the viruses abrogated the requirement for growth factors and suppressed c-myc expression.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930972     DOI: 10.1038/317434a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  41 in total

1.  Drastically increased expression of MYC and FOS protooncogenes during in vitro differentiation of chronic lymphocytic leukemia cells.

Authors:  L G Larsson; H E Gray; T Tötterman; U Pettersson; K Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

Review 2.  Control of myogenic differentiation by cellular oncogenes.

Authors:  M D Schneider; E N Olson
Journal:  Mol Neurobiol       Date:  1988       Impact factor: 5.590

3.  Truncation of the c-myb gene by a retroviral integration in an interleukin 3-dependent myeloid leukemia cell line.

Authors:  Y Weinstein; J N Ihle; S Lavu; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

4.  In vitro proliferation of human large granular lymphocytes with v-raf/v-myc recombinant retrovirus.

Authors:  S Peppoloni; E Blasi; J R Ortaldo; U R Rapp; C Riccardi; L Varesio
Journal:  Experientia       Date:  1988-12-01

5.  Splenic accumulation of interleukin-3-dependent hematopoietic cells in Friend erythroleukemia.

Authors:  C Spiro; B C Gliniak; D Kabat
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.

Authors:  G Pernegger; T F Schulz; M Hosp; B L Myones; A L Petzer; A Eigentler; G Böck; G Wick; M P Dierich
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

7.  Dissociated expression of c-myc and a fos-related competence gene during cardiac myogenesis.

Authors:  M D Schneider; P A Payne; H Ueno; M B Perryman; R Roberts
Journal:  Mol Cell Biol       Date:  1986-11       Impact factor: 4.272

8.  Interleukin-3-stimulated haemopoietic stem cell proliferation. Evidence for activation of protein kinase C and Na+/H+ exchange without inositol lipid hydrolysis.

Authors:  A D Whetton; S J Vallance; P N Monk; E J Cragoe; T M Dexter; C M Heyworth
Journal:  Biochem J       Date:  1988-12-01       Impact factor: 3.857

9.  Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression.

Authors:  D Eick; G W Bornkamm
Journal:  Nucleic Acids Res       Date:  1986-11-11       Impact factor: 16.971

10.  Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human.

Authors:  K Huebner; A ar-Rushdi; C A Griffin; M Isobe; C Kozak; B S Emanuel; L Nagarajan; J L Cleveland; T I Bonner; M D Goldsborough
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.